Navigation Links
Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences' Patented Pressure Cycling Technology (PCT)
Date:4/4/2013

d the work of Dr. McCord and his team, which could potentially accelerate the development and launch of the PCT-based Rape Kit Processing System; that improved rape kit testing methods might lead to the arrests of perpetrators sooner, which would prevent their involvement in rape and other violent crimes; and the size of the life sciences sample preparation market. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported or see the advantages of using the Company's PCT platform in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond May 2013. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond May 2013 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under
'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medifirst Solutions, Inc. Announces Further Update To Shareholders
2. Probiotic Action Announces Further Exploration of Probiotics for Acne with New Information from the LA Times
3. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
4. UCLA researchers further refine NanoVelcro device to grab single cancer cells from blood
5. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
6. China Cord Blood Corporation to Further Consolidate its Corporate Structure
7. OxThera Raises Capital for Further Clinical Development of Oxabact(R)
8. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
9. USPTO Grants Butamax a Further KARI Enzyme Patent
10. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
11. P&G Beauty & Grooming to present advancements in skin aging & stress sweat at AAD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... IN (PRWEB) , ... July 01, 2015 , ... Apex ... 2015 BIO International Convention in Philadelphia, PA. , The presentation took place ... and outlined the plans for the development of APX3330 for the treatment of pancreatic ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students ... part in the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught ... summer 2014, this course combines students from both universities and is taught on ...
(Date:6/30/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a ... address unmet medical needs in women,s health, today ... present at the Cantor Fitzgerald Inaugural Healthcare Conference ... 4:45 PM EDTLocation: , Le Parker Meridien Hotel, ... www.juniperpharma.com, under  ,Investor, or  click here ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... , , ROCKVILLE, Md. , ... of the PARADIGM trial, a Phase 2 clinical study ... of individuals with suspected central nervous system infection due ... held biotechnology company that develops immunotherapeutics to treat autoimmune ...
... SYDNEY, July 12 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... to voluntarily de-list from the Nasdaq Global,Market ("Nasdaq"). , ... review of the demand from existing and,potential international investors ... on Nasdaq and the volume of Pharmaxis ADS trading,in ...
... ,PROVIDENCE, R.I. [Brown University] Rashid Zia, assistant professor ... winners of the Presidential Early Career Awards for Scientists ... of winners this week. The PECASE award recognizes ... show exceptional potential for leadership at the frontiers of ...
Cached Biology Technology:MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Pharmaxis to Voluntarily De-List from Nasdaq 2Brown engineering professor wins prestigious White House award 2
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... The largest genome-wide association study ever conducted on ... has identified 16 new genetic associations related to ... 23andMe, the leading personal genetics company, and the ... examined data for more than 53,000 individuals. The ...
... who give birth vaginally are at increased risk of developing ... a study of Chinese women by researchers at Yale School ... online July 1 in the British Journal of Obstetrics ... labor and delivery made the pelvic floor relax and not ...
... that the key to treating neurodegenerative prion diseases such ... in the ribosome, the protein synthesis machinery of the ... Journal of Biological Chemistry . Prion diseases are ... Examples of prion diseases are scrapie in sheep, mad ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3Vaginal delivery ups risk of pelvic organ prolapse 2The ribosome -- a new target for antiprion medicines 2
... (Human Exonic Evidence Based Oligonucleotide) Genome Set ... ) Genome Set contain a collection of ... constitutively expressed exons, allowing interrogation of thousands ... researchers at Stanford University and UCSF, the ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: